Dana Farber Cancer Insitute
Boston, United States
Matthew Meyerson, M.D., Ph.D., is Professor of Genetics at Harvard Medical School, Director of the Center for Cancer Genomics at the Dana-Farber Cancer Institute, and an Institute Member of the Cancer Program at the Broad Institute. His laboratory at the Dana-Farber Cancer Institute has focused on understanding the cancer genome and its implications for cancer therapeutics.
Over the past decades, Dr. Meyerson and colleagues have discovered genes and gene alterations important in human cancer, including the human cyclin-dependent kinase family including CDK2 and CDK6, the human telomerase catalytic subunit gene TERT, somatic mutations in lung cancer in EGFR, U2AF1, RBM10, HLA genes and others, somatic mutations in glioblastoma in EGFR, and copy number alterations across cancer including lineage amplifications. The current focus of the Meyerson laboratory is on somatic alterations in the non-coding cancer genome, on the cancer microbiome, and on genome-inspired cancer drug discovery.
The Meyerson laboratory has pioneered technical and computational approaches for cancer genome research, including methods for copy number determination with single nucleotide polymorphism (SNP) arrays, the first next-generation sequencing analysis of cancer DNA and the computational subtraction approach for discovery of novel disease-causing microbes.
Dr. Meyerson received his M.D. from Harvard Medical School and his Ph.D. from Harvard University. He served as a resident in Clinical Pathology at Massachusetts General Hospital and a post-doctoral fellow at the Whitehead Institute with Dr. Robert Weinberg. Among other prizes, Dr. Meyerson has been awarded the Paul Marks Prize in Cancer Research from Memorial Sloan-Kettering Cancer Center, the Team Science Award from the American Association for Cancer Research, and the Knudson Prize in Cancer Genetics from the National Cancer Institute. Dr. Meyerson is a member of the National Academy of Medicine, the Association of American Physicians, and the American Society for Clinical Investigation.